AlphAIAlphAI — Financial news for AI agents
tipranks.comSEP 162 min read$DFTX

Definium Therapeutics Logs Third Positive Phase 3 Readout for DT120 in Anxiety

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 in treating generalized anxiety disorder, showing significant improvement over placebo. The company plans to meet with the FDA in Q4 2026 and submit a new drug application in early 2027, aiming for a potential best-in-class treatment.

Original reporting
tipranks.com
Published Sep 16, 2026, 11:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 5:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Definium Therapeutics Logs Third Positive Phase 3 Readout for DT120 in Anxiety — source image
Source · tipranks.com
Decision brief

The 30-second read

$DFTXBullishMed
01

Why it matters

The Phase 3 readout provides the first pivotal efficacy evidence, setting the stage for an NDA.

02

Market read

Positive trial data is a strong catalyst for the stock and may influence the broader mental‑health biotech space.

03

What to watch

Potential competition from other single‑dose anxiolytics could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Definium Therapeutics is a clinical‑stage biotech developing DT120 for anxiety and depression.

Company-level read

Ticker impact

$DFTXBullishHigh confidence
Context

Definium Therapeutics reported positive Phase 3 topline results for DT120 in generalized anxiety disorder.

Expected impact

Potential upside of 15‑25% if data leads to NDA filing.

Evidence & confidence

Phase 3 success is a material catalyst for a biotech with no prior approval.

Market effects

Sector

Strengthens the anxiety‑treatment segment and may lift peer biotech stocks.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to investors focused on mental‑health therapeutics.

Counterpoint

What could challenge this read

If regulatory scrutiny intensifies, the data may not translate into approval.

Key entities

  • company
    Definium Therapeutics

    Biotech developer of DT120.

  • regulator
    U.S. Food and Drug Administration

    Will review the upcoming NDA.

Read at source← All news

Related articles

SEP 14
$DFTXMedAI 9/10

Definium's DT120 ODT Achieves Significant Anxiety Improvement In Phase 3 Trial; Stock Up

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder, meeting primary and secondary endpoints. The study showed significant reduction in HAM-A scores with a 5.1-point placebo-adjusted improvement. The company plans to submit a New Drug Application in early 2027. DFTX stock rose 3.07% to $38.89 on Friday and is up 13.40% in pre-market trading.

rttnews.com2 min
SEP 14
$DFTXHighAI 9/10

Why is Definium Therapeutics stock surging today?

Definium Therapeutics (DFTX) stock surged 20.7% in pre-market trading after its Phase 3 trial of DT120 ODT for generalized anxiety disorder met its primary endpoint. The company has also received FDA Breakthrough Therapy designation for DT120 in major depressive disorder. Analysts had previously assigned Buy or Strong Buy ratings, with price targets above current levels. The stock is nearing its 52-week high of $49.70, up from a low of $8.77.

investing.com2 min
SEP 14
$DFTXMedAI 9/10

Definium Therapeutics stock jumps on positive trial results

Definium Therapeutics (DFTX) shares rose 20% after reporting positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The study met primary and secondary endpoints, showing a 5.1-point reduction in anxiety scores. The drug was well-tolerated, with a safety profile consistent with prior trials. The company plans to file for FDA approval in 2027.

investing.com2 min
SEP 13
$DFTXLow

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

Definium Therapeutics (DFTX) will host a webcast on September 14, 2026, to discuss topline results from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder. The study enrolled 245 participants across 32 centers, with primary endpoints focused on changes in HAM-A and CGI-S scores. Definium Therapeutics is a Nasdaq-listed biopharmaceutical company developing psychiatric and neurological disorder treatments.

owensoundsuntimes.com1 min